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T cell response 
A B S T R A C T   
Cancer vaccines aim to efficiently prime cytotoxic CD8+ T cell responses which can be achieved by vaccine 
targeting to dendritic cells. CD169+ macrophages have been shown to transfer antigen to dendritic cells and 
could act as an alternative target for cancer vaccines. Here, we evaluated liposomes containing the CD169/ 
Siglec-1 binding ligand, ganglioside GM3, and the non-binding ligand, ganglioside GM1, for their capacity to 
target antigens to CD169+ macrophages and to induce immune responses. CD169+ macrophages demonstrated 
specific uptake of GM3 liposomes in vitro and in vivo that was dependent on a functional CD169 receptor. Robust 
antigen-specific CD8+ and CD4+ T and B cell responses were observed upon intravenous administration of GM3 
liposomes containing the model antigen ovalbumin in the presence of adjuvant. Immunization of B16-OVA tumor 
bearing mice with all liposomes resulted in delayed tumor growth and improved survival. The absence of 
CD169+ macrophages, functional CD169 molecules, and cross-presenting Batf3-dependent dendritic cells 
(cDC1s) significantly impaired CD8+ T cell responses, while B cell responses were less affected. In conclusion, we 
demonstrate that inclusion of GM3 in liposomes enhance immune responses and that splenic CD169+ macro-
phages and cDC1s are required for induction of CD8+ T cell immunity after liposomal vaccination.   
1. Introduction 
Although checkpoint inhibitors have emerged as a powerful immu-
notherapy for cancer patients, the majority of cancer patients still do not 
benefit from this treatment regimen [1–3]. A combination of immuno-
therapy with checkpoint inhibitors and a cancer vaccination strategy is 
expected to act synergistically via activation of immune responses [4–7]. 
A variety of vaccine strategies have been explored to induce anti- 
cancer immune responses [8]. To stimulate cytotoxic CD8+ T cells, 
vaccine-delivered tumor antigens need to be presented by cross- 
presenting DCs (cDC1) in an effective manner. Unfortunately, this 
process is often suboptimal, exposing a bottleneck in cancer vaccine 
development [9,10]. Our previous research has revealed that cross- 
presenting cDC1 collaborate with CD169+ (Siglec-1/Sialoadhesin) 
macrophages in the spleen to induce adaptive immune responses. We 
and others have observed that antigens targeted to CD169+ macro-
phages were efficiently transferred to cDC1 and elicited potent CD8+ T 
cell responses that inhibited tumor outgrowth [11–14]. In addition, the 
direct induction of anti-tumor T cell responses by CD169+ macrophages 
has also been proposed [14,15]. These observations suggest that vac-
cines that are efficiently taken up by CD169+ macrophages may opti-
mally stimulate anti-tumor immunity. 
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The primary function of CD169+ macrophages located in the lymph 
nodes and spleen is to scavenge pathogens and endogenous sialic acid- 
containing particles from the lymph fluid and blood, respectively 
[16–18]. The CD169 receptor binds sialylated glycoproteins and gly-
colipids present on the pathogen surface [19]. Binding of HIV virions to 
human CD169 is mediated via a host-derived sialylated glyco-
sphingolipid, the ganglioside GM3 [20–22]. Previously, GM3 was 
identified as a high affinity binder to mouse CD169 and GM1 ganglioside 
as a non-binder [23–25]. 
Liposomes are an attractive antigen delivery system and have 
already been verified as an effective vaccination platform [26–28]. The 
aim of the present study was to selectively deliver antigen to splenic 
CD169+ macrophages using i.v. administered liposomes containing 
GM3 as targeting molecule. We have evaluated the uptake, the immu-
nogenic capacity, and anti-tumor reactivity of control, GM3 and GM1 
liposomes containing ovalbumin (OVA) protein as an antigen encapsu-
lated in the liposome core. In addition, we performed mechanistic 
studies, which revealed important roles of CD169+ macrophages, the 
CD169 receptor and Batf3-dependent cDC1s in the activation of CD8+ T 
cell responses after vaccination with these liposomes. Our findings shed 
light on the mechanisms responsible for the immunogenicity of lipo-
somes and aid further optimization of liposomal cancer vaccines. 
2. Materials and methods 
2.1. Mice 
C57Bl6/J and Batf3KO mice obtained from Charles River or the 
Jackson Laboratory. W2QR97A mutant animals, also referred to in the 
text as CD169 mutant animals, harboring two amino acid substitutions 
(Trp2 to Gln, Arg97 to Ala) in the CD169 receptor were generated at 
University of Dundee (Dundee, Scotland) [29]. CD169-DTR mice were 
generated by Dr. M. Tanaka from the Tokyo University of Pharmacy and 
Life Sciences (Tokyo, Japan) [30,31]. All mouse lines were bred were 
bred at the animal facility of Amsterdam UMC (Amsterdam, The 
Netherlands). Mice used in the study predominantly females between 8 
and 12 weeks of age. For CD169-DTR experiments, heterozygous mice 
were administered or not (control) with diphtheria toxin (DT) two days 
prior to immunization. All animals were kept under specific pathogen- 
free conditions and used in accordance with local animal experimenta-
tion guidelines. 
2.2. Liposome preparation and characterization 
Liposomes were prepared from a mixture of phospholipids and 
cholesterol utilizing the film extrusion method as described previously 
[76]. In brief, during the first step of the preparation, egg phosphati-
dylcholine (EPC)-35 (Lipoid), egg phosphatidylglycerol (EPG)-Na (Li-
poid) and Cholesterol (Sigma-Aldrich) were mixed at a molar ratio of 
3.8:1:2.5, combined with 0,1 mol% of the lipophilic fluorescent tracer 
DiD (1′-dioctadecyl-3,3,3′,3′-tetramethyl indodicarbocyanine, Life 
Technologies) and where indicated with 3 mol% GM3 ganglioside 
(monosialodihexosylganglioside) (Avanti Polar Lipids) or 3 mol% GM1 
ganglioside (monosialotetrahexosylganglioside) (Avanti Polar Lipids). A 
solution of 4 mg/ml or 1 mg/ml Ovalbumin (OVA, Calbiochem) was 
encapsulated into liposomes during the hydration step, as described 
previously (Unger et al., 2012). In order to obtain liposomes of 
approximately 200 nm, hydrated preparations were sequentially 
extruded through stacked 400 and 200 nm polycarbonate filters using 
high-pressure extrusion device. Next, to remove non-encapsulated 
gangliosides and OVA, the liposomal solutions were pelleted in an ul-
tracentrifuge (Beckman) for 60 min at 200,000 g. In between the 
centrifugation steps, after removal of the supernatant, the pellet was 
resuspended in fresh Hepes buffer pH 7.5 containing 50 U/ml penicillin 
and 50 μg/ml streptomycin (Lonza). Obtained in the following way li-
posomes were exposed to quality control analysis where size, 
polydispersity index and zeta potential were determined using dynamic 
light scattering (DLS) (Zetasizer Nano ZSP) (Malvern Instruments). 
2.3. Sandwich ELISA for OVA content determination 
OVA encapsulation efficiency was determined in an sandwich ELISA. 
MaxiSorp ELISA plates (NUNC, Denmark) were coated with 1 μg/ml 
purified anti-chicken Ovalbumin (OVA, Biolegend) in coating buffer 
(pH 9.2) o/n at 4 ◦C. The following morning the plates were washed with 
PBS containing 0.05% Tween20 and blocked with 1% BSA/PBS for 1 h at 
RT. Diluted in PBS liposomes and standard OVA (Sigma), were treated 
with 0.1% Triton-X for 1 h at RT on a shaking plate. Washed with 0.05% 
Tween20/PBS plates were incubated with serial dilutions of Triton-X- 
treated liposomes and OVA standard for 1 h at RT on a shaking plate. 
Next, the plates were washed with 0.05% Tween20/PBS and incubated 
with polyclonal rabbit anti-OVA Ig for 1 h at RT on a shaking plate. After 
washing, goat-anti-rabbit IgG-HRP (Thermofisher) was added for 30 min 
at RT on a shaking plate and the plates were washed with 0.05% 
Tween20/PBS. To develop the reaction, 100 μg/ml of TMB (Sigma- 
Aldrich) was used as a substrate. The absorbance was measured at 450 
nm using microplate absorbance spectrophotometer (Biorad). The 
amount of encapsulated OVA was calculated as 13–15 μg/ml liposomes, 
reaching loading efficiency of approximately 0.2%. 
2.4. CD169 Fc and PNA ELISA 
MaxiSorp ELISA plates (NUNC, Denmark) were coated with 25 μmol 
liposomes dissolved in 100% ethanol and left to air dry overnight. The 
following morning the plates were blocked with 1% BSA/PBS (Fraction 
V, Fatty acid free, Calbiochem) and washed with PBS. Next, for CD169- 
Fc ELISA the plates were incubated with 2 μg/ml mouse CD169 Fc WT or 
R97A mutant conjugate (mouse CD169 fused to Fc fragment of human 
IgG1, in house-made) for 1 h at RT and directly after PO goat anti-human 
IgG-Fc (Thermo Fisher Scientific) in 1% BSA/PBS was added for 30 min 
at RT. For PNA ELISA, the plates were incubated with 5 μg/ml PNA- 
biotin (Vector laboratories) for 1 h at RT and directly after 
streptavidin-HRP (Invitrogen) in 1% BSA/PBS was added for 30 min at 
RT. After the incubation, the plates were washed with PBS. To develop 
the reaction, 100 μg/ml of TMB (Sigma-Aldrich) was used as a substrate. 
The absorbance was measured at 450 nm using microplate absorbance 
spectrophotometer (Biorad). 
2.5. Liposome uptake by CD169-expressing CHO cells 
CD169-expressing WT and R97A mutant Chinese hamster ovary cells 
(CHO cells) (gift from Prof. Paul R. Crocker, Dundee, Scotland) were 
maintained in RPMI-1640 (Gibco, Life Technologies) supplemented with 
10% FCS (Biowest), 50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM L- 
glutamine (all Lonza) and 1 mg/ml G418 (Santa Cruz). Following har-
vesting, the cells were seeded in 96-well plates at 1 × 105 cells/well. 
Prior to liposome incubation, CHO WT cells were incubated with 10 μg/ 
ml of blocking anti-CD169 Ab (clone SER-4, in-house made) for 20 min 
at 4 ◦C. Next, 0.1 mmol liposomes in HBSS containing 0.5% BSA were 
added to the cells for 60 min at 37 ◦C. Following two washing steps, the 
cells were stained with Fixable Viability Dye eFlour 780 (eBioscience) 
and measured using Fortessa (BD Biosciences) FACS analyser. Flow 
cytometry analysis was performed using FlowJo software (Tree Star). 
2.6. Spleen digestion 
Spleens of WT and W2QR97A mutant mice were digested as previ-
ously described [12]. Briefly, mechanistically dissociated spleens were 
digested using a mixture of 4 mg/ml Lidocaine, 2 WU/ml Liberase TL 
(Roche, Germany) and 50 μg/ml DNase I (Roche, Germany) for 15 min 
at 37 ◦C with continuous stirring. After adding RPMI-1640 (Gibco, Life 
Technologies) supplemented with 10% heat-inactivated FCS (Biowest), 
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10 mmol EDTA, 20 mmol HEPES and 50 μM 2-mercaptoethanol, sple-
nocytes were incubated for additional 10 min at 4 ◦C with continuous 
stirring. Next, red blood cells were lysed using ammonium-chlor-
ide‑potassium (ACK) lysis buffer and splenocytes were filtered through 
70–100 μm filter. 
2.7. Liposome binding to splenocytes 
For in vivo liposome binding assay, mice were immunized i.v. with 
93 nmol of control-OVA or GM3 and GM1 ganglioside-containing OVA 
liposomes in presence of 25 μg of poly(I:C) and 25 μg anti-CD40 Ab 
(clone 1C10). Two hours after liposome administration the mice were 
sacrificed and the spleens were collected. Digested splenocytes were 
seeded in 96-well plates at 3 × 106 cells/well for flow cytometry. For in 
vitro liposome binding assay, digested splenocytes were seeded in 96 
wells at 3 × 106 cells/well and incubated 10 μg/ml of blocking anti- 
CD169 Ab (clone SER-4, in-house made) for 20 min at 4 ◦C. Subse-
quently, 0.1 mmol liposomes in HBSS/0.5% BSA were added to the cells 
for 60 min 4 ◦C or 37 ◦C. Following two washing steps with PBS/0.5% 
BSA, the cells were stained for flow cytometry. 
2.8. Immunofluorescence microscopy 
To obtain tissue sections for immunofluorescence microscopy, spleen 
blocks cryopreserved in liquid nitrogen were cut at 5–6 μm thickness 
using CryoStar NX70 (Thermo Scientific). After blocking of unspecific 
binding with 10% normal goat serum in PBS for 20 min at RT, tissue 
sections were stained with anti-CD169-Alexa Fluor 488 (clone SER-4, in- 
house made) and anti-B220-biotin (clone RA3-6B2, BD Biosciences) for 
45 min at RT. Next, the slides were incubated with a Alexa Fluor 555- 
conjugated streptavidin for 30 min at RT, followed by incubation with 
DAPI for 10 min at RT. Mounted with a coverslip slides were analyzed 
with Leica DM6000 using 10× objective. LAS AF software was used for 
image acquisition and processing. Exposure time for DiD signal was 
adjusted using tissue sections of uninjected mice, while for the adjust-
ment of the exposure times for other channels unstained tissue sections 
were used. The following filter cubes/fluorochromes combinations were 
used: A4/DAPI, L5/Alexa Fluor 488, N3/Alexa Fluor 555 and Y5/DiD. 
2.9. Evaluation of antigen-specific T cell and B cell responses 
To investigate antigen-specific T cell and B cell responses, WT, 
CD169-DTR, CD169 mutant mice and Batf3KO mice were injected i.v. 
with 93 nmol and 200 nmol respectively of control-OVA or ganglioside- 
containing OVA liposomes in presence of 25 μg of poly(I:C) and 25 μg 
anti-CD40 Ab (clone 1C10). For immunization experiments performed 
in CD169-DTR model, the mice were administered with 40 ng/g of DT i. 
v. 2 days pre-immunization with liposomes. On day 7 p.i., splenocytes 
were collected as previously described [12]. Digested splenocytes were 
seeded in 96-well plates at 3 × 106 cells/well and used for direct 
tetramer staining, direct germinal center B cell staining and intracellular 
IFNγ staining following re-challenge with OVA peptide in vitro. Identi-
fication of OVA-specific CD8+ T cell and B cell responses was directly 
performed by flow cytometry. For determination of CD8+ and CD4+ T 
cell responses following re-challenge with cognate peptide, the cells 
were incubated with MHC class I restricted OVA 257–264 peptide (0.1 
μg/ml) in presence of GolgioPlug (BD Biosciences) for 5 h or with MHC 
class II restricted OVA 262–276 peptide (100 μg/ml) for 23 h with last 5 
h also in presence of GolgiPlug (BD Biosciences). Next, flow cytometry 
staining was performed. 
2.10. Determination of anti-OVA titer in the serum 
To determine the anti-OVA Ig titer in the serum of liposome- 
immunized mice, serum was obtained by centrifugation of blood 
collected on day 7 p.i.. MaxiSorp ELISA plates (NUNC, Denmark) were 
coated with 5 μg/ml OVA (Sigma-Aldrich) in sodium phosphate buffer 
(Na2HPO4, NaH2PO4 and MiliQ, pH 6.5) o/n at 4 ◦C. The following 
morning the plates were washed with 0.05% Tween20/PBS and blocked 
with 1% BSA/PBS for 1 h at RT. After washing, serial dilutions of serum 
in 1% BSA/PBS were incubated for 2 h at RT. Next, rabbit anti-mouse Ig- 
HRP (Dako) in 1% BSA/PBS was added to the washed plates for 1 h at 
RT. To develop the reaction, 100 μg/ml of TMB (Sigma-Aldrich) was 
used as a substrate. The absorbance was measured at 450 nm using 
microplate absorbance spectrophotometer (Biorad). An average + 3×
SD of OD values measured in blank wells without serum OD value was 
assigned as a cut-off value. Antibody titers were determined as dilutions 
with corresponding OD values higher than the cut-off. 
2.11. Flow cytometry 
Cells were first incubated with 10 μg/ml of anti-CD16/32 (clone 
2.4G2, in-house made) for 15 min at 4 ◦C to block unspecific Fc receptor 
binding and subsequently stained with an appropriate surface antibody 
panel containing a Fixable Viability Dye eFlour 780 (eBioscience) in 
PBS/0.5% BSA for 30 min at 4 ◦C. To identify specific immune cell 
populations in the spleen, the cells were stained with antibodies or 
fluorescent reagents provided in Table 1. For direct identification of 
OVA-specific CD8+ T cells using H-2Kb/SIINFEKL tetramers, cells were 
stained at 37 ◦C for 60 min. To evaluate OVA-specific B cell responses, 
cells were stained at 4 ◦C for 30 min. For intracellular IFNγ staining, first 
surface staining was performed. The cells were fixed with 2% para-
formaldehyde (Electron microscopy science) for 20 min at 4 ◦C, per-
meabilized with 0.5% Saponin solution and stained for intracellular 
cytokine. After washing the cells were measured using Fortessa (BD) 
FACS analyser. Flow cytometry analysis was performed using FlowJo 
software (Tree Star). 
2.12. Tumor challenge and therapeutic vaccination 
Melanoma B16-OVA cells (kind gift from Prof. T.N. Schumacher, 
Netherlands Cancer Institute) [32] were maintained in RPMI-1640 
(Gibco, Life Technologies) supplemented with 10% FCS (Biowest), 50 
U/ml penicillin and 50 μg/ml streptomycin, 2 mM L-glutamine (all 
Lonza) and passaged at 70% confluency. Eight weeks old C57Bl6/J 
animals were injected subcutaneously (s.c.) in the flank with 3 × 105 
B16-OVA cells in 100 μl HBSS. Tumor dimensions were measured by 
digital caliper 3× per week and used to calculate tumor volume with 
modified ellipsoid formula: L x W^2 x PI/6 [33]. Mice were sacrificed 
when tumor reached humane end point (HEP), thus size 800–1000 mm3. 
On day 9, when tumors were palpable (tumor size range 0,5–30 mm3), 
the mice were randomized into treatment groups (average size of 12,5 
mm3) and immunized i.v. with 93 nmoles of OVA-containing liposomes 
in presence of 25 μg of poly(I:C) and 25 μg anti-CD40 Ab (clone 1C10). 
Seven days after vaccination, blood was collected from the cheek to 
determine the expansion of antigen-specific CD8+ T cells. Obtained 
blood cells were centrifuged, exposed to ACK lysis buffer to remove red 
blood cells and stained with CD8+ T cell tetramer antibody mixture. 
2.13. Statistical analysis 
Statistical significance was determined in GraphPad Prism software 
using one-way ANOVA test with Bonferroni’s multiple comparison test 
or two-way ANOVA test with Tukey’s multiple comparison test (*p <
0.05, **p < 0.01). All values are expressed as ±SEM with individual 
mice showed. 
3. Results 
3.1. GM3 liposomes specifically bind to CD169 in vitro 
We generated small anionic liposomes containing ovalbumin protein 
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(OVA) in the aqueous core and carrying 3 mol% of ganglioside mole-
cules GM3 or GM1 and 0.1 mol% of the lipophilic DiD dye in the bilayer 
(Fig. 1A-C). The inclusion of GM3 or GM1 did not affect the zeta po-
tential, size and the polydispersity index of the liposomes compared to 
control liposomes. Ganglioside GM3 with a terminally oriented α2,3- 
linked sialic acid group was included as a primary CD169 targeting 
ligand since it was previously shown to mediate specific recognition of 
virus particles by CD169 [34]. Contrary to ganglioside GM3, ganglioside 
GM1 contains an internally positioned sialic acid residue resulting in a 
weak CD169 interaction, and therefore served as a negative control, next 
to the non-targeting control liposomes [25]. 
To confirm the incorporation of gangliosides into the liposomes and 
subsequently assess their binding specificity to CD169, we performed an 
ELISA assay using recombinant CD169 Fc WT and CD169 Fc mutant 
protein, which harbors mutations in the ligand binding part of the re-
ceptor (R97A) rendering it incapable of sialic acid recognition [29]. As 
Table 1 
List of antibodies/fluorescent reagents used for flow cytometry.  
Antigen/reagent Fluorochrome Clone Company Panel 
CD169 Alexa Fluor 488 SER-4 in-house made Macrophage/DC/B cell/liposome 
B220 Alexa Fluor 405 6B2 in-house made 
F4/80 PE-CF594 T45–2342 BD Biosciences 
CD8a PE-Cy7 53–6.7 BD Biosciences 
CD11c BV650 HL3 BD Biosciences 
I-A/I-E PE M5/114.15.2 eBioscience 
I-A/I-E Alexa Fluor 405 M5/114 in-house made 
CD11b PE-Cy7 M1/70 eBioscience NK cell/T cell/monocyte/liposome 
Ly6C/Gr-1 eFluor 450 RGG6-8C5 eBioscience 
CD3 FITC 145-2C11 eBioscience 
NK 1.1 BV650 PK136 BD Biosciences 
CD8a APC 53–6.7 BD Biosciences CD8+ T cell tetramer staining 
CD44 FITC KM81 Immunotools 
H-2Kb/SIINFEKL PE tetramer N/A LUMC, Leiden 
B220 BV510 RA3-6B2 Biolegend Germinal B cell staining 
CD38 PE 90/CD38 BD Biosciences 
GL7 PE-Cy7 GL-7 Biolegend 
OVA Alexa Fluor 488 N/A Invitrogen 
CD11a FITC M17/4 eBioscience Re-stim intracellular IFNγ staining 
CD8a PE-Cy7 53–6.7 BD Biosciences 
CD4 PE GK1.5 eBioscience 
IFNγ APC XMG1.2 eBioscience  
Fig. 1. Characterization of the liposomal formulations. A. Schematic representation of control and ganglioside liposomes composed of phospholipid bilayer 
(cholesterol not shown) incorporated with ganglioside GM3 and GM1 structures and lipophilic DiD tracer (red glow) encapsulating ovalbumin protein (OVA) in the 
aqueous core. Gal, galactose; Glu, glucose; GalNAc, N-Acetylgalactosamine; NeuAc, sialic acid; GM3, ganglioside GM3; GM1, ganglioside GM1. B. Determination of 
particle size, PDI (polydispersity index) and zeta potential of prepared liposomal formulations. The data are from five batches of liposomes used in the study. C. 
Determination of the amount of encapsulated OVA in batches prepared with 1 mg/ml OVA, expressed in ng per ml of liposomal solution. The data are of minimum 
four batches, from three experiments. D-E Binding of liposomes to WT and mutant CD169 Fc conjugates (D) and PNA (E) determined by ELISA. The data are mean of 
triplicates from three (D) and four (E) different batches of liposomes. PNA, peanut agglutinin. F. Uptake of liposomes by CD169-expressing CHO WT and CHO mutant 
cells illustrated by DiD geometric mean fluorescence intensity (gMFI). The data are from one experiment representative of two experiments. Error bars indicate mean 
± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni’s multiple comparison test (A-C,F) and two-way ANOVA with Tukey’s multiple comparison test (D- 
E)). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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previously reported, GM3 liposomes demonstrated high binding to 
CD169 Fc WT, while no binding to CD169 Fc mutant was observed 
(Fig. 1D). GM1 liposomes, similarly to control liposomes, did not bind to 
either of the recombinant CD169 Fc conjugates. To validate inclusion of 
ganglioside GM1 into the nanoparticle bilayer, we performed a lectin 
ELISA with peanut agglutinin (PNA), which specifically binds terminal 
β1,3-linked galactose [35]. As expected, only GM1 liposomes containing 
such structure bound to PNA, while control and GM3 liposomes did not 
(Fig. 1E). 
Next, we evaluated the binding of liposomes to cell-surface expressed 
CD169 using a CD169-expressing CHO cell line transfected with CD169 
WT or R97A mutant CD169 (Fig. 1F). CHO CD169 WT cells displayed 
very high DiD levels after incubation with GM3 liposomes in comparison 
to control and GM1 liposomes. In contrast, CHO CD169 R97A mutant 
cells did not take up GM3 liposomes. Accordingly, antibody-mediated 
blocking of the CD169 receptor largely diminished GM3 liposome 
capture. 
Subsequently, we analyzed liposome binding and uptake by sple-
nocytes ex vivo. While CD169 is highly expressed on CD169+ macro-
phages, F4/80+ red pulp macrophages display low expression of the 
receptor (Fig. S1). As expected, when we compared liposome binding at 
4 ◦C and uptake at 37 ◦C, we observed an evident increase in liposome 
uptake at 37 ◦C (Fig. 2A and gating strategy in Fig. S2). This effect was 
most pronounced with GM3 liposomes as illustrated by increase in 
geometric mean fluorescence intensity (gMFI) of DiD, but we also 
observed some uptake of GM1 liposomes. Ex vivo CD169+ macrophages 
sequestered extremely high levels of GM3 and significant lower levels of 
GM1 and control liposomes. Red pulp F4/80+ macrophages and espe-
cially cDC1 capture much lower amounts of GM3 liposomes when 
compared to CD169+ macrophages. Antibody-mediated blocking of the 
CD169 receptor (data not shown) and use of splenocytes isolated from 
mice expressing the W2QR97A mutant CD169 receptor (referred to as 
CD169 mutant) prevented uptake of GM3 liposomes by CD169+ mac-
rophages as well as by F4/80+ red pulp macrophages and cDC1 (Fig. 2B 
and Fig. S3A). In contrast, other cell populations including cDC2, B cells, 
monocytes, T cells and NK cells displayed no liposome binding (data not 
shown). 
In summary, these results clearly show that in vitro GM3 liposomes 
bind selectively to CD169 receptors, preferentially expressed by CD169+
macrophages, whereas GM1 and control liposomes bind much lower or 
not to CD169+ expressing cells. 
3.2. Uptake of GM3 liposomes by CD169+ macrophages in vivo is 
mediated by CD169 
To determine whether GM3 liposomes are taken up by splenic 
CD169+ macrophages in vivo, we i.v. administered control and gangli-
oside liposomes together with an adjuvant (anti-CD40/poly(I:C)) into 
WT and CD169 mutant animals (Fig. 3 and Fig. S3B). At 2 h post in-
jection (p.i.), GM3 liposomes were predominantly sequestered by 
CD169+ macrophages and to a substantially lesser extent by F4/80+ red 
pulp macrophages, while hardly any liposome uptake was detected in 
cDC1. Contrary to the in vitro binding, CD169+ macrophages also 
captured control and non-targeted GM1 liposomes in vivo, however the 
GM3 liposome uptake was more than three-fold higher (Fig. 3A). As 
expected, this increased uptake of GM3 liposomes by CD169+ macro-
phages did not occur in CD169 mutant animals. Overall, these results 
indicate superior CD169-mediated uptake of GM3 liposomes as 
compared to non-CD169-mediated uptake of all liposomes. Liposome 
capture by cDC2, B cells, monocytes, T cells and NK cells was very low 
and appeared not to be dependent on the ganglioside modification of the 
liposome surface (Fig. S3B and data not shown). 
Microscopic analysis of the spleen sections 2 h p.i. corroborated the 
flow cytometry data revealing clear co-localization of GM3 liposomes 
with CD169+ macrophages in the marginal zone and lower association 
of control and GM1 liposomes with this macrophage subset (Fig. 3B). 
Similar to the 2 h time point, at 16 h p.i. CD169+ macrophages displayed 
the highest GM3 liposome uptake when compared to other cell types. 
Furthermore, GM3 liposome uptake was significantly higher compared 
to control and GM1 liposomes also at 16 h p.i. (Fig. S3C). 
Fig. 2. GM3 liposomes are taken up by CD169+ macrophages in a CD169-dependent manner in vitro. A. In vitro binding (4 ◦C) and uptake (37 ◦C) of liposomes to 
splenocytes determined by flow cytometry. B. In vitro uptake (37 ◦C) of liposomes by WT and CD169 mutant splenocytes determined by flow cytometry. The graphs 
show quantification of DiD gMFI. The data are from one experiment (A, n = 5) and from one experiment representative of three (B, n = 3). Each symbol represents 
one mouse. Error bars indicate mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni’s multiple comparison test). 
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Taken together, these data demonstrate that CD169+ macrophages 
efficiently capture liposomes in vivo and that the incorporation of GM3 
significantly further enhances liposome uptake in a CD169-dependent 
fashion. 
3.3. GM3 liposomes elicit superior immune responses in the presence of 
adjuvant 
Next, we investigated the immunostimulatory capacity of the lipo-
somes. To this end, WT animals were injected i.v. with OVA-containing 
GM3, non-targeting GM1 and control liposomes in the presence of a 
potent adjuvant combination, anti-CD40 and poly(I:C). Antigen-specific 
T cell and B cell responses in the spleen were determined 7 days after 
immunization. The magnitude of OVA-specific CD8+ and CD4+ T cell 
activation was measured with H-2Kb-SIINFEKL tetramer staining and 
intracellular IFNγ staining upon ex vivo re-challenge with cognate pep-
tides. Additionally, we evaluated the OVA-specific germinal center B cell 
response and OVA-specific antibody titers. The flow cytometry analysis 
of tetramer staining revealed significantly higher frequencies of OVA- 
specific CD8+ T cells in GM3 liposome-treated animals as compared to 
mice immunized with GM1 and control liposomes (Fig. 4A and gating 
strategy in Fig. S4). We observed a similar trend in the percentages of 
OVA-specific IFNγ producing CD8+ and CD4+ T cells, although this ef-
fect appeared not significant (Fig. 4A-B). In addition, significantly 
higher numbers of OVA+ germinal center B cells were induced by im-
munization with GM3 and GM1 liposomes, when compared to control 
liposomes (Fig. 4C). Accordingly, we measured highest anti-OVA Ig ti-
ters in the serum of GM3 liposome-immunized mice (Fig. 4C and S5). 
Immunization with OVA-containing control and ganglioside lipo-
somes in the absence of the adjuvant revealed negligible induction of 
Fig. 3. GM3 liposomes are taken up by CD169+ macrophages in a CD169-dependent manner in vivo. A-B WT and CD169 W2QR97A mutant (CD169 mutant) mice 
were injected i.v. with 70 nmoles liposomes (OVA 4 mg/ml) in the presence of adjuvant (25 μg anti-CD40 and 25 μg poly(I:C)). Uptake of liposomes in the spleen 
determined 2 h p.i. by flow cytometry (A) and microscopy (B). The graphs show quantification of DiD gMFI. The data are representative of two experiments (n = 3). 
Each symbol represents one mouse. Error bars indicate mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni’s multiple comparison test). 
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OVA-specific T and B cell immunity (data not shown). This observation 
is in line with multiple cancer vaccination studies that demonstrate the 
necessity of adjuvant for immune activation [36–38]. Having demon-
strated the importance of adjuvant in our vaccination platform, we next 
assessed the impact of liposomal antigen encapsulation on its immu-
nogenicity. To address this, we immunized mice with GM3 and control 
OVA-containing liposomes or different doses of soluble OVA in the 
presence of adjuvant and evaluated immune activation on day 7 p.i. 
(Fig. S6). Liposomal-encapsulated OVA, equivalent to 0,2 μg of protein, 
proved to be more potent than 10 μg soluble OVA as illustrated by 
significantly higher frequency of antigen-specific T and B cells. 
Collectively, these data indicate superior capacity of GM3 liposomes 
over non-targeted GM1 and control liposomes to stimulate effector T and 
B cell responses in the presence of adjuvant. 
3.4. Liposomes delay tumor outgrowth, reduce tumor burden and improve 
survival in B16-OVA tumor model 
Having demonstrated potent immune-activating capacity of the GM3 
liposomes in naïve mice, we hypothesized that these nanoparticles show 
efficacy in a tumor setting. To test this idea, WT mice were injected 
subcutaneously into the flank with 3 × 105 OVA-expressing B16 tumor 
cells and once palpable tumors had developed (day 9), the mice were 
immunized with a single dose of OVA-containing liposomes and anti- 
CD40/poly(I:C) adjuvant (Fig. 5 and S7). Tumor growth and survival 
were monitored for 39 days. Strikingly, already 7 days after a single 
vaccination we observed significant reduction of tumor burden and 
delayed tumor growth in all treatment groups that maintained until day 
25 post tumor inoculation (Fig. 5A-B). The decrease of tumor burden 
coincided with pronounced expansion of SIINFEKL+ CD8+ T cells in the 
blood of liposome-treated mice (Fig. 5C). Observed CD8+ T cell response 
Fig. 4. GM3 liposomes elicit robust immune responses upon co-administration with adjuvant. A-C WT mice were injected i.v. with 93 nmoles liposomes (OVA 1 mg/ 
ml) in the presence of adjuvant (25 μg anti-CD40 and 25 μg poly(I:C)) and the immune responses in the spleen were determined on day 7 p.i. by flow cytometry. A. 
Percentage of H-2Kb-SIINFEKL-tetramer+ CD8+ T cells and percentage of OVA-specific IFNγ-producing CD8+ T cells. B. Percentage of OVA-specific IFNγ-producing 
CD4+ T cells after in vitro re-challenge. C. Percentage of OVA-specific germinal center B cells (left) and serum titer of OVA-specific total Ig determined by ELISA 
(right). The data are from three experiments combined, n = 14 (left) and two experiments combined, n = 10 (right). Each symbol represents one mouse Error bars 
indicate mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni’s multiple comparison test). 
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was of similar magnitude in all treatment groups, which correlates with 
the similar potency in tumor growth inhibition. Finally, tumor-bearing 
mice immunized with our OVA-containing liposomes exhibited signifi-
cantly improved survival (Fig. 5D). These data clearly demonstrate the 
anti-tumor capacity of here evaluated liposome-based vaccine upon 
systemic administration. 
3.5. CD169+ macrophages bearing a functional CD169 receptor mediate 
generation of antigen-specific CD8+ T cells after liposome vaccination 
After examining the immune responses induced by liposomes in 
naïve and tumor-bearing mice, our next aim was to elucidate the un-
derlying immune mechanism. Since CD169+ macrophages were the 
main liposome-internalizing cell type in vivo, we first determined the 
importance of this macrophage subset in the liposome-mediated im-
mune activation. To address this, we made use of the CD169-DTR mouse 
model that allows for selective depletion of CD169-expressing cells upon 
diphtheria toxin (DT) administration. Microscopic and flow cytometry 
analysis of the spleen tissue 48 h post DT injection confirmed successful 
elimination of CD169+ cells leaving other cells unaffected (Fig. S8). 
Upon immunization with control and ganglioside liposomes co-injected 
with adjuvant, a significant decrease in the generation of OVA-specific 
CD8+ T cells was detected when CD169+ macrophages were depleted 
as detected by H-2Kb/SIINFEKL tetramer binding as well as OVA-specific 
IFNγ production (Fig. 6A). Interestingly, this was observed for all lipo-
some types. Surprisingly, CD4+ T cell and B cell immunity appeared not 
to be influenced by the absence of CD169+ macrophages (Fig. 6B-C). 
Since GM3 liposomes were sequestered by CD169+ macrophages in a 
CD169-dependent fashion (Fig. 3), we hypothesized a role for CD169 in 
GM3 liposome-induced immunity. We immunized WT and CD169 
mutant animals with OVA-containing control and ganglioside liposomes 
in the presence of adjuvant (Fig. 6D-E). CD169 mutant mice contained 
comparable numbers of CD169+ macrophages and DCs compared to WT 
animals (Fig. S1). Upon i.v. administration of GM3 liposomes, WT mice 
exhibited significantly higher OVA-specific CD8+ and CD4+ T cell re-
sponses compared to CD169 mutant mice, as illustrated by intracellular 
IFNγ staining and tetramer staining (Fig. 6D). Apparently, the decrease 
in uptake of GM3 liposomes by mutant CD169+ macrophages is directly 
translated into lower T cell responses. A similar trend, although not 
significant, was observed in animals immunized with control and GM1 
liposomes. We have previously demonstrated a role for CD169 in the 
collaboration between CD169+ macrophages and Batf3-dependent 
cDC1s after antigen-antibody targeting [12]. The results obtained here 
suggest that a CD169-mediated interaction may also play a minor role 
for T cell responses induced by control and GM1 liposomes that are 
taken up by CD169+ macrophages in a CD169-independent manner. 
Finally, when we examined OVA-specific germinal center B cell re-
sponses triggered by GM3 liposomes, we detected significantly dimin-
ished numbers of OVA+ germinal center B cells in the mice bearing a 
mutated version of CD169 receptor, in comparison to WT animals 
(Fig. 6F). Although total anti-OVA Ig responses were not affected at this 
early time point, this finding suggests that CD169-mediated antigen 
uptake by CD169+ macrophages also promotes germinal center B cell 
immunity. 
In conclusion, together these data demonstrate that CD169+ mac-
rophages are essential for CD8+ T cell priming after liposomal vacci-
nation and that a functional CD169-receptor is necessary for GM3 
liposome-mediated enhanced CD8+ and CD4+ T cell as well as 
germinal center B cell immune responses. 
3.6. cDC1 are essential for CD8+ T cell responses induced by GM3 
liposomes 
The previous experiments demonstrated an important role for 
CD169+ macrophages in CD8+ T cell priming. CD169+ macrophages 
could be directly involved in antigen presentation to and activation of 
CD8+ T cells or alternatively could collaborate with cDC1 for CD8+ T 
cell priming as previously observed in antibody-mediated antigen tar-
geting [12]. To evaluate the role of cDC1 in liposome-induced immu-
nity, we measured immune responses in WT and Batf3KO mice i.v. 
immunized with OVA-containing control and ganglioside liposomes in 
presence of the adjuvant. OVA-specific CD8+ T cell responses were 
inhibited to background levels in Batf3KO animals compared to WT 
animals for GM3, GM1 and control liposomes, as illustrated by tetramer 
and intracellular IFNγ staining (Fig. 7A). While the absence of cDC1 
during liposome immunization also negatively affected the generation 
of IFNγ producing CD4+ T cells (Fig. 7B), this was not the case for the 
OVA-specific germinal center B cell population and antibody titers 
(Fig. 7C). 
In conclusion, these results confirm the crucial role of Batf3- 
Fig. 5. Therapeutic vaccination with liposomes de-
lays tumor growth and improves survival. A-D WT 
mice were s.c. inoculated in the flank with 3 × 105 
B16-OVA tumor cells. On day 9 after tumor challenge, 
when tumors were palpable, the mice were injected i. 
v. with 93 nmoles liposomes (OVA 1 mg/ml) in 
presence of adjuvant (25 μg anti-CD40 and 25 μg poly 
(I:C)). A. Tumor growth curves determined by size 
measurements performed three times per week until 
day 39 using a caliper. Statistical comparison illus-
trated performed on day 39 after tumor challenge. B. 
Overall survival. C–D Mean tumor size (C) and per-
centage of H-2Kb-SIINFEKL-tetramer+ CD8+ T cells in 
blood (D) determined 7 days after immunization, on 
day 16 after tumor challenge. The data are from one 
experiment with no treatment, n = 13; control-OVA, 
n = 11; GM3-OVA, n = 10; GM1-OVA n = 13. Each 
symbol represents one mouse. Error bars indicate 
mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA 
with Bonferroni’s multiple comparison test).   
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dependent cross-presenting DCs for generation of potent CD8+ T cell 
responses triggered not only by GM3 liposomes, but also by control and 
non-targeted GM1 liposomes. 
4. Discussion 
The enormous progress in cancer immunotherapy in the last decade 
has emphasized the importance of a strong anti-tumor CD8+ T cell 
response to achieve tumor eradication [39]. Current challenges in the 
field focus on the induction or the improvement of CD8+ T cell activa-
tion in checkpoint inhibitor-treated cancer patients by combining it with 
a synergistic strategy, such as cancer vaccination. Although DCs are 
favored targets for antigen delivery to induce antigen-specific immunity 
[9,40,41], CD169+ macrophages have emerged as an attractive alter-
native to antigen presenting cells for antigen targeting. We and others 
have previously shown that CD169+ macrophages efficiently capture 
pathogens and antibody-conjugated antigens from lymph fluid and 
blood and stimulate robust CD8+ T cell responses in collaboration with 
cross-presenting DC1s [11–14,16,42]. 
Here we demonstrate for the first time that these two cell types are 
also responsible for CD8+ T cell priming after liposomal vaccination. We 
show that CD169+ macrophages not only efficiently take up CD169- 
targeted GM3-containing liposomes, but also non-targeted liposomes. 
Our studies further indicate that CD169+ cannot activate CD8+ T cell 
Fig. 6. CD169+ macrophages expressing a functional CD169 receptor orchestrate GM3 liposome-induced CD8+ T cell activation. A-C CD169-DTR mice were injected 
or not i.v. with 40 ng/g mouse of diphtheria toxin (DT) on day 0 and with 93 nmoles liposomes (OVA 1 mg/ml) in presence of adjuvant (25 μg anti-CD40 and 25 μg 
poly(I:C)) on day 2. The immune responses in the spleen were determined on day 7 p.i. with liposomes by flow cytometry. D–F WT and W2QR97A mutant (CD169 
mutant) mice were injected i.v. with 93 nmoles liposomes (OVA 1 mg/ml) in presence of adjuvant (25 μg anti-CD40 and 25 μg poly(I:C)) and the immune responses in 
the spleen were determined on day 7 p.i.. by flow cytometry. A,D Percentage of H-2Kb-SIINFEKL-tetramer+ CD8+ T cells and percentage of OVA-specific IFNγ- 
producing CD8+ T cells. B,E Percentage of OVA-specific IFNγ-producing CD4+ T cells after in vitro re-challenge. C,F Percentage of OVA-specific germinal center B cells 
(left) and serum titer of OVA-specific total Ig determined by ELISA (right). The data are from two experiments combined, n = 10 (A-C) and n = 9 (D–F). Each symbol 
represents one mouse. Error bars indicate mean ± SEM. *p < 0.05, **p < 0.01 (one-way ANOVA with Bonferroni’s multiple comparison test). 
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responses by themselves, but require the presence of Batf3-dependent 
cDC1s for CD8+ T cell priming. Since we did not investigate the mech-
anism of this mutual requirement for induction of CD8+ T cells, we can 
only speculate about the processes that could mediate such interde-
pendency. One possibility is that CD169+ macrophages, that are 
apparently specialized in liposome uptake from the blood, efficiently 
transfer captured liposomes to cDC1s, which are present in close prox-
imity due to interaction with CD169 receptor via sialic acids [12]. 
Nevertheless, we did not detect clear changes in cDC1-associated DiD 
fluorescence in WT animals at 16 h p.i. (from 2 h), neither in DT-treated 
CD169-DTR mice (data not shown) nor in CD169 mutant mice, which 
would support or disprove the antigen transfer hypothesis. However, 
care must be taken when interpreting these findings as DiD is located in 
the bilayer and thus may follow different routes than the encapsulated 
protein antigen upon liposome disintegration. An alternative explana-
tion for the requirement of both CD169+ macrophages and cDC1 could 
be that CD169+ macrophages enhance the capacity of cDC1s to cross- 
present and subsequently activate CD8+ T cells e.g. via the production 
of type I interferons [43–46]. Future studies are necessary to elucidate 
the exact mechanism(s) underlying cooperation between CD169+ mac-
rophages and cDC1s after liposomal vaccination. 
Another surprising result from our studies is that although CD169+
are essential for CD8+ T cell priming, these cells appeared not to be 
necessary for activation of B cell immunity upon liposomal challenge. In 
a number of seminal studies, lymph node CD169+ macrophages were 
shown to present antigen to B cells and we previously reported strong B 
cell responses after antibody-mediated antigen targeting to CD169+
macrophages, which were eliminated after treatment with clodronate 
liposomes [47–50]. In line with this, here we observed induction of 
antigen-specific B cells after enhanced targeting to CD169+ macro-
phages using GM3 liposomes (Fig. 4) but, unexpectedly, B cell responses 
remained unaffected in CD169-DTR mouse model (Fig. 6). It has to be 
noted that the CD169 depletion experiments are difficult to interpret as 
in the absence of CD169+ macrophages we detected higher uptake of 
liposomes by all other cell types (data not shown). This suggests that the 
clearance rate of liposomes is significantly decreased in the absence of 
CD169+ macrophages. Furthermore, the removal of CD169+ macro-
phages, which are located on top of the B cell follicles, may dramatically 
change the localization of liposomes and subsequent uptake patterns, 
and thus precludes clear comparison between both conditions. Aside of 
these considerations, another mechanism of B cell activation that is in-
dependent of CD169+ macrophages could well be operational in our 
liposomal vaccination strategy. Marginal zone B cells are known to 
transport immune complexes into B cell follicles [51–53] and a 
complement-IgM-dependent pathway has also been described for the 
transport of PEGylated liposomes by marginal zone B cells [54,55]. 
Therefore, a complement-dependent B cell activation that is indepen-
dent of CD169+ macrophages may be involved after liposomal 
vaccination. 
Systemically administered nanoparticles interact with plasma pro-
teins resulting in a protein layer adsorbed on the surface of nano-
particles, also known as the protein corona (reviewed by [56–58]). 
Although nanoparticles carrying a positive charge exhibit an increased 
association with serum proteins, a protein corona is also formed on 
anionic nanoparticles. Since the protein corona has been found to 
modulate nanoparticle characteristics and behavior in vivo, it might also 
affect here investigated liposomes. Opsonization and complement acti-
vation could potentially be involved in the non-CD169 receptor-medi-
ated uptake of control and GM1 liposomes by CD169+ macrophages, 
observed in vivo. Complement factors and various plasma proteins 
enriched in serum affect liposome internalization via opsonin receptor- 
dependent mechanism involving complement system and Fc receptors 
[59]. In fact, anionic liposomes are potent stimulators of complement 
system and complement component C1q and scavenger receptors have 
been previously implicated in the sequestration of intravenously injec-
ted anionic nanoparticles by antigen presenting cells [60–62]. Thus, 
complement-mediated mechanisms could potentially be responsible for 
the in vivo uptake of anionic liposomes by macrophages and their ca-
pacity to elicit immune responses in the presence of adjuvant. 
One of the primary aims of this study was to investigate the effect of 
specific antigen targeting to CD169+ macrophages using GM3 liposomes 
on immune responses and tumor reactivity. Our data clearly shows the 
Fig. 7. Cross-presenting DCs orchestrate liposome-induced CD8+ T cell activation. WT and Batf3KO animals were injected i.v. with 200 nmoles liposomes (OVA 4 
mg/ml) in presence of adjuvant (25 μg anti-CD40 and 25 μg poly(I:C)) and the immune responses in the spleen were determined on day 7 p.i.. by flow cytometry. A. 
Percentage of H-2Kb-SIINFEKL-tetramer+ CD8+ T cells and percentage of OVA-specific IFNγ-producing CD8+ T cells. B. Percentage of OVA-specific IFNγ-producing 
CD4+ T cells after in vitro re-challenge. C. Percentage of OVA-specific germinal center B cells (left) and serum titer of OVA-specific total Ig determined by ELISA 
(right). The data are from two experiments combined, n = 6. Each symbol represents one mouse. Error bars indicate mean ± SEM. *p < 0.05, **p < 0.01 (one-way 
ANOVA with Bonferroni’s multiple comparison test). 
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importance of a functional CD169 receptor for enhanced GM3 liposome 
uptake by these macrophages in vitro and in vivo as well as augmented 
CD8+ T cell and B cell responses. While we observed a strong inhibition 
of tumor outgrowth in all vaccinated mice, we did not detect enhanced 
tumor reactivity of GM3 liposomes when compared to control or GM1 
liposomes. In the present study we systemically co-injected liposomes 
with a very potent adjuvant, which may augment immune response 
induced by less efficient targeted liposomes i.e. control and GM1 lipo-
somes, possibly compromising the potential efficacy of CD169 targeting. 
Future studies in which we will combine antigen and adjuvant in one 
CD169+ macrophage-targeting nanoparticle may exhibit better efficacy. 
Recently, Edgar, Kawasaki [63] investigated CD169-targeted nano-
particles bearing a synthetic high affinity ligand for CD169. The authors 
showed that selective liposomal delivery of both the antigen and toll-like 
receptor 7 agonist (TLR7 agonist) to CD169+ macrophages drove effi-
cient CD8+ T cell expansion. This suggests that incorporation of TLR7 
ligand may further enhance the activity of GM3 liposomes. Ganglioside 
GM3 offers an important advantage over a synthetic molecule as CD169 
ligand. Being widely expressed in the body, GM3 will not elicit an im-
mune response, in contrast to foreign molecules incorporated in lipo-
somes such as PEG, which upon repeated administration causes adverse 
hypersensitivity reactions [64]. 
Our results demonstrating enhanced targeting of GM3 liposomes to 
CD169+ macrophages in vivo are in line with human in vitro studies using 
GM3-containing nanoparticles, which reported specific binding to 
human CD169-expressing macrophages and monocyte-derived DCs 
[20,22,65]. We recently showed that several ganglioside-containing li-
posomes can bind to ex vivo human splenic macrophages as well as 
blood-derived Axl+ Siglec-6-expressing DCs and subsequently activate 
CD8+ T cells [66]. Furthermore, here presented findings verify the 
selectivity of GM3 for CD169/Siglec-1, as we did not observe binding to 
other Siglec receptors expressed by various other cell types such as DCs, 
B cells and NK cells [19]. Multiple studies have shown that marginal 
zone CD169+ macrophages are the predominant cell type to capture 
viruses including HIV, MLV and Ebola additionally revealing ganglio-
sides as mediators of the binding to CD169 [46,67–71]. Similarly, GM3 
liposomes can be regarded as virus-like nanoparticles that appear to 
selectively bind to CD169 receptor. 
Currently, a multitude of liposome-based vaccine vectors that 
display different characteristics are being tested as anti-cancer thera-
peutics [8,72]. In fact, negatively charged RNA-lipoplexes have been 
shown to successfully target splenic macrophages and DCs when 
administered i.v. resulting in potent (anti-cancer) CTL responses in mice 
and in humans [73–75]. Importantly, our studies demonstrate the 
crucial role of CD169+ macrophages and cross-presenting cDC1s for the 
immune responses induced by liposomes. In addition, we show that the 
addition of GM3 to anionic liposomes significantly enhances antigen 
delivery to splenic CD169+ macrophages and subsequent induction of 
CD8+ T cell immunity. Further elucidation of the cellular interactions in 
lymphoid organs after vaccine uptake will expand our knowledge on the 
immunogenicity of nanoparticle-based antigen targeting platforms and 
will guide optimal nanoparticle design for cancer vaccination. 
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